Randall K. Johnson, Ph.D.Independent Consultant
Randall K. Johnson, Ph.D, has over 30 years of experience in government and industry. Dr. Johnson has worked in all aspects of cancer drug discovery and development. This experience ranges from target validation, through screening technologies, basic research on mechanisms of drug action, assessment of efficacy in preclinical tumor models, to clinical development plans and regulatory strategies. He has put many oncology drugs into clinical development and is credited with bringing topotecan to market. Dr. Johnson is currently a consultant to the pharmaceutical and biotechnology industries, focused on anticancer drug discovery and development. Previously, Dr. Johnson was Group Director of the Department of Oncology Research at GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania. Dr. Johnson earned his Ph.D. in pharmacology from George Washington University, Washington DC. Prior to his twenty year tenure at GlaxoSmithKline, Dr. Johnson was Section Head, Laboratories of Experimental Chemotherapy and Chemical Pharmacology at the National Cancer Institute, Bethesda, Maryland, and Manager, Experimental Therapeutics Section, Biological Research and Technology Department at Arthur D Little, Inc., Cambridge, Massachusetts.
